APOLLO HOSPITALS ENTER. L vs ORCHID PHARMA LIMITED

A side-by-side comparison of APOLLO HOSPITALS ENTER. L (APOLLOHOSP) and ORCHID PHARMA LIMITED (ORCHPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, APOLLO HOSPITALS ENTER. L leads APOLLOHOSP vs ORCHPHARMA on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

65.36
P/E ratio
257.12
13.42
P/B ratio
3.86
0.11%
Dividend yield
0.00%
₹135.04
EPS
₹4.05

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

22.10%
Return on equity
2.12%
18.00%
Return on capital
3.00%
15.00%
EBITDA margin
5.00%
7.94%
Net margin
2.59%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
6.79%
33.39%
Profit CAGR (3Y)
-23.00%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.27L Cr
Market cap
₹5,259 Cr
₹25,228 Cr
Revenue
₹811 Cr
₹2,003 Cr
Net profit
₹21 Cr
0.90
Debt / equity
0.28
APOLLO HOSPITALS ENTER. L
  • + ["Company has delivered good profit growth of 77.8% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
  • ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
ORCHID PHARMA LIMITED
  • ["Stock is trading at 3.99 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend", "Tax rate seems low", "Company has a low return on equity of 6.41% over last 3 years.", "Company might be capitalizing the interest cost", "Earnings include an other income of Rs.28.6 Cr.", "Promoter holding has decreased over last 3 years: -20.1%"]
APOLLO HOSPITALS ENTER. L full analysis ORCHID PHARMA LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.